DelveInsight’s Sepsis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Sepsis Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Sepsis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Sepsis can be the clinical manifestation of infections acquired both in the community setting and in health care facilities. It is a subset of Sepsis in which underlying circulatory and cellular/metabolic abnormalities are profound enough to increase mortality substantially. Patients with septic shock can be identified with a clinical construct of Sepsis with persisting hypotension requiring vasopressors to maintain mean arterial pressure (MAP) ≥65 mm Hg and having a serum lactate level >2 mmol/L (18 mg/dL) despite adequate volume resuscitation.
Get access to a free copy of our latest sample report @ https://www.delveinsight.com/sample-request/sepsis-market
Some of the key facts of the Sepsis Market Report
- According to DelveInsight’s analysis, males are affected more as compared to females (Except the US).
- Assessments indicate that 57% of all cases were sepsis without organ dysfunction followed by septic shock (24.63%) and severe sepsis (18.37%) in the United States in 2018.
- In 2020, the total 7MM cases of sepsis was estimated to be 3,400,940. These cases are expected to increase in 2030 growing at a CAGR of 2.11% for the study period of 2018–2030.
Sepsis market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of Sepsis in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Sepsis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Sepsis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Sepsis Market Insights
Sepsis is a medical emergency; in other words, Sepsis should be treated as quickly and efficiently as possible. Treatment for Sepsis varies, depending on the site and cause of the initial infection, the organs affected, and the extent of any damage. Sepsis treatment is generally examined under two main headings: appropriate antimicrobial treatment and all-purpose supporting treatment. The treatment for Sepsis includes several antibiotics to fight infection, vasoactive medications to increase blood pressure, insulin to stabilize blood sugar, and painkillers. In severe cases of Sepsis, extracorporeal therapies are also used.
Sepsis Treatment Market
The main treatment for Sepsis, Severe Sepsis, or septic shock is antibiotics. Ideally, antibiotic treatment should start within an hour of diagnosis to reduce the risk of serious complications or death. Broad-spectrum antibiotics are the first-line medications. These antibiotics are combinations of two or three antibiotics given simultaneously; most combinations usually include vancomycin to treat many MRSA and other antibiotic-resistant (drug-resistant) infections.
The epidemiology section covers insights about the historical and current Sepsis patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Sepsis Drugs & Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sepsis market or expected to get launched in the market during the study period. The analysis covers Sepsis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Sepsis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Sepsis Emerging Therapy Assessment
The approved drugs for sepsis are not very much, and in the emerging pipeline it was seen that many drugs in the pipeline failed to show any improvement in the clinical trial. The main reason for the failure of the trials was selection for primary endpoint, but in new trials the primary endpoint was to determine the change observed at the 28-day all-cause mortality rate compared to the placebo control group. In the potential therapies that can be launched in the forecasted period, we have considered Fetroja/Fetcroja (Cefiderocol), Recombinant human alkaline phosphatase, Nangibotide (LR12), Adrecizumab, and CYT107. Apart from these few approved therapies are also there, i.e., GIAPREZA (angiotensin II), Vasostrict (vasopressin), and Empressin (Argipressin). The peak share of all these therapies is based on their targeted patient pool (severe sepsis, septic shock and overall sepsis).
Sepsis Market Companies includes-
- La Jolla Pharmaceuticals
- Par Pharmaceutical
- Ono Pharmaceutical
- Vivacelle Bio
- Enlivex Therapeutics
- Adrenomed, and others
Sepsis Therapies includes-
- Onoact Injection (Landiolol hydrochloride)
- Nangibotide (LR12)
- Adrecizumab, and others
View Detailed Report of key players and therapies @ https://www.delveinsight.com/sample-request/sepsis-market
Sepsis Market Drivers
- Rising Incidence
- Innovations in R&D strategies
- Increasing awareness
- Expected approval of pipeline drugs in the forecasted period
- Understanding of Sepsis pathophysiology
Sepsis Market Barriers
- Delay in diagnosis due to the lack of a gold standard test
- Disease burden associated with the high cost of treatment
- Limitations associated with defining sepsis
- Trial Failures and Drug withdrawal from the market
Table of content
- Key Insights
- Executive Summary
- Competitive Intelligence Analysis
- Market Overview at a Glance
- Disease Background and Overview
- Patient Journey
- Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Unmet Needs
- Key Endpoints of Sepsis Treatment
- Marketed Products
- Emerging Therapies
- Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview
- KOL Views
- Market Drivers
- Market Barriers
- DelveInsight Capabilities
- About DelveInsight
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States